Background Randomized clinical trials have demonstrated that the efficacy of a fixed-dose single-tablet combination containing sumatriptan and naproxen sodium (S/NS) was greater than either of its individual components. Simplifying drug regimens (e.g., via a fixed-dose combination) has been shown to improve ''real-world'' outcomes by reducing pill burden and treatment regimen complexity, improving adherence, and reducing healthcare resource use and associated costs; however, no studies assessing such outcomes have been conducted to date for the acute treatment of migraine. Objective To assess migraine-related healthcare resource use and associated costs for subjects prescribed S/NS vs. subjects prescribed single-entity oral triptans (SOTs) within a managed care population in the USA.
Introduction
As one of the most prevalent neurologic disorders in the world, migraine is the result of a complex pathophysiology involving changes in both the central and peripheral nervous systems. Migraines are characterized by episodic headaches associated with moderate-to-severe head pain and symptoms such as nausea, vomiting, and sensitivity to light and/or noise. Global estimates of the prevalence of migraine vary from 5 to 15 %, which translates to nearly 1 billion migraine sufferers worldwide [1, 2] . In the USA, the prevalence is approximately 11 % of the general population [3] [4] [5] [6] , with women disproportionally impacted (prevalence range, men vs. women: 5.6-6.5 vs. 17-18.2 %) [7] [8] [9] .
As the epidemiology of migraine has been extensively studied, so has the burden of illness. The individual and societal burden of migraine is substantial, especially considering that, while affecting all ages, migraine prevalence peaks between the ages of 25 and 55 years, reflecting the most productive working years for those experiencing migraines [5, 7, 10] . Current estimates of the burden of migraine are approximately US$19.6 billion and €27 billion per year in the USA and Europe, respectively [11] [12] [13] . These estimates reflect the high prevalence of the disorder and the substantial economic burden. However, it is the indirect cost component, caused by absence from work (absenteeism) and reduced productivity while at work (presenteeism) , that accounts for the largest share of overall total costs (up to 90 % of total costs) [5, [14] [15] [16] [17] [18] . On a perpatient basis, the direct medical costs (e.g., drug treatment, physician costs, diagnostics, and emergency room visits) associated with migraine vary from US$581 to US$7,089 per year [19] [20] [21] [22] . Categorized by setting of care, Insinga and colleagues estimated the mean cost for migraine-related care per outpatient visit was US$140; per emergency room visit was US$775; and per inpatient hospitalization was US$7,317 [23] .
Given the substantial economic burden of migraine, it is of critical importance that physicians, patients, and healthcare decision makers (e.g., payers) identify optimal strategies for managing migraines, whether it be acute treatment, preventive treatment, behavioral approaches (e.g., avoidance of migraine triggers), or a combination of strategies. From the perspective of acute treatment, the US Headache Consortium identified the goals of treatment as the following: treat attacks rapidly and consistently without recurrence; restore the patient's ability to function; minimize the use of back-up and rescue medications; optimize self-care and reduce subsequent use of resources; be cost effective for overall management; and have minimal or no adverse effects [24, 25] . To this point, well-designed randomized clinical trials have shown that the oral triptans are an effective acute migraine treatment [26] [27] [28] and, along with the non-steroidal anti-inflammatory drugs (NSAIDs) and ergots, have been identified as the most effective acute migraine therapies [24, 29, 30] . In addition to these therapies, a wide range of non-specific acute migraine therapies (e.g., aspirin, acetaminophen, opioids, butalbital, isometheptene, antihistamines, antinauseants, antiepileptics, muscle relaxants) have been shown to alleviate migraine pain and associated symptoms; [25] albeit many of these therapies lack regulatory approval for the acute treatment of migraine.
The difference in the underlying mechanisms of action of these various medications and their ability to alleviate the pain and symptoms of migraine confirms the complex pathophysiology of migraine, as well as demonstrating that, when administered as monotherapy, none of the currently available, acute migraine treatments provides broad coverage of the multiple pathogenic processes of the condition. Thus, it is hypothesized that a fixed-dose combination of medications with differing mechanisms of action may provide a synergistic benefit that, when used in combination, may offer advantages over monotherapy resulting in improved patient outcomes. For example, two commonly used migraine therapies, oral triptans and NSAIDs, target distinct aspects of the vascular and inflammatory processes hypothesized to underlie migraine. Triptans reduce calcitonin gene-related peptide-mediated vasodilation, inhibit release of inflammatory mediators from trigeminal nerves, and decrease transmission of pain impulses to the trigeminal nucleus caudalis [31] [32] [33] . NSAIDs inhibit the synthesis of prostaglandins and may mitigate meningeal inflammation while preventing or reversing central sensitization arising from the activation of glial cells in the brain stem [31, 34, 35] .
The hypothesis of a synergistic effect has been demonstrated in randomized clinical trials of a fixed-dose singletablet combination containing sumatriptan succinate (equivalent to sumatriptan 85 mg) and naproxen sodium 500 mg (S/NS), where the efficacy of the combination was greater than either of its individual components [31, [36] [37] [38] and resulted in improved overall outcomes measured in terms of satisfaction, productivity, and quality of life [39] [40] [41] .
In theory, simplifying drug regimens (e.g., via a fixeddose combination) should improve ''real-world'' outcomes by reducing pill burden and the complexity of treatment regimens, improving patient adherence, and saving healthcare resource use and associated costs. This has been demonstrated in various therapeutic categories, such as diabetes mellitus, HIV/AIDS, and cardiovascular disease [42] [43] [44] [45] [46] [47] [48] [49] , but not the acute treatment of migraine, in part owing to the lack of approved fixed-dose combination products. In this regard, the objective of the analyses presented in this paper is to assess migraine-related healthcare resource use and associated costs for subjects prescribed S/NS vs. single-entity oral triptans (SOTs) within a managed care population in the USA.
Methods

Study Design and Data Source
In this retrospective cohort study (GlaxoSmithKline study TRX113913), administrative claims and enrollment records from the IMS LifeLink Ò Health Plan Claims Database (formerly the PharMetrics Integrated Outcomes Database) were analyzed for the period of July 1, 2008 through December 31, 2009 . The data contain medical claims (e.g., inpatient, outpatient, emergency department, physician office, skilled nursing facility, durable medical equipment, and home health), pharmacy claims, and associated costs from over 90 national, managed care health plans covering approximately 60 million lives across the USA. All claims from participating managed care organizations undergo rigorous data quality review, all patient identifiers in the database have been fully encrypted (thereby maintaining patient confidentiality), and the database is fully protected under the Health Insurance Portability and Accountability Act of 1996. Data elements include date of service, place of service, diagnosis codes (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM]), procedure codes (ICD-9-CM, Current Procedural Terminology [CPT] and Healthcare Common Procedure Coding system [HCPC] formats), provider specialty, national drug codes, drug quantity dispensed, days supplied, charged and paid amounts, and co-payments, as well as details on individuals' dates of health plan enrollment (medical and pharmacy) and demographic characteristics (e.g., age, gender, region, payer type). The database is geographically diverse and is considered to be representative of the commercially insured population in the USA (http://www.imshealth. com).
Study Population
Data from July 1, 2008 to December 31, 2009 were used in this study. Subjects with at least one pharmacy claim for either S/NS (''S/NS group'') or SOT (''SOT group'') were identified between January 1, 2009 and June 30, 2009. The service date of the first observed pharmacy claim of interest was defined as the index date. The study population was identified based on subjects meeting the following inclusion criteria: (1) aged 18-64 years; (2) had at least one migraine diagnosis in the pre-or post-index period (ICD-9-CM diagnosis code: 346.xx, excluding 346.3x [hemiplegic migraine] and 346.5x [persistent migraine aura without cerebral infarction]); and (3) had continuous enrollment in the health plan (medical and pharmacy) for the 6 months prior to and 6 months post the index date. Finally, subjects with a pharmacy claim for any nasal triptan at any time during the study period, subjects with pharmacy claims for two or more different SOTs on the same index date, and subjects in the SOT group with a post-index S/NS pharmacy claim were excluded.
The study population was subsequently stratified for analyses based on the triptan-naïve and triptan-switch populations. For the triptan-naïve analysis, in addition to meeting the requirements stated above, subjects were required to be triptan naïve (no S/NS or SOT pharmacy claims) in the 6-month period prior to their index date. For the triptan-switch analysis, subjects were eligible for the analysis if they had a pharmacy claim for a SOT between July 1, 2008 and December 31, 2008 that was different from the medication identified on the index date. These subjects were identified as ''existing SOT users'' and considered to be switchers.
Study Measures
The primary outcome measure considered for this study was migraine-specific healthcare resource use and associated costs during the 6-month post-index period. Migrainespecific healthcare resource use was defined as: (1) Migraine-specific costs, stratified by total, pharmacy, and medical, were assessed in the 6-month post-index period. As this study was conducted from a payer perspective, the cost data represent actual amounts reimbursed by the payer to the providers. All cost estimates were adjusted to 2009 US dollars using the medical care component of the Consumer Price Index.
Other Variables
Demographic and clinical characteristics were assessed at the index date and included the following: age, gender, geographic region, and comorbidities. Comorbidity measures included the Charlson Comorbidity index (CCI) [50] [51] [52] [53] , a unique count of disease states based on three-digit ICD-9-CM diagnosis codes beyond those defined in the CCI, and the presence of comorbid depression or anxiety based on ICD-9-CM diagnosis codes (depression: 296.2x, 296.3x, 300.4x or 311.xx; anxiety 300.01, 300.21, 300.22, 300.23, 300.3x, 309.81, 308.3x and 300.02). Three assessments of migraine severity were also examined. The first assessment calculated the mean number of migraine medications (measured in terms of tablets) in the 6-month pre-index period, categorized by medication type: triptan (including S/NS), NSAID (excluding S/NS), opioid, antiemetic, and prophylactic medications. The second assessment of migraine severity was based on the migrainespecific Medstat Disease Staging score, where the scoring algorithm was based on ICD-9-CM diagnosis codes and higher scores representing greater severity (Disease Staging Clinical Criteria. 4th Edition. Ann Arbor, MI: Thomson Medstat). The final assessment of migraine severity was based on migraine-related healthcare resource use and costs that occurred in the 6-month pre-index period. Allcause healthcare resource use and associated costs were also estimated for the 6-month pre-index period.
Statistical Analyses
Descriptive statistics were generated for all analysis variables, including frequency distributions for categorical variables and mean values and standard deviations (SDs) for continuous variables. Differences between the S/NS and SOT groups were tested using chi-square tests for categorical variables and Student t tests and/or analysis of variance tests for continuous variables. These comparisons were performed for both the unmatched and matched samples.
Matching was performed using propensity scores to balance the distribution of observed confounders across the two groups, thereby reducing the possibility of selection bias caused by observed baseline differences between subjects who received S/NS vs. those who received SOT. For the triptan-naïve analysis, one S/NS subject was matched to three SOT subjects (1:3); and for the triptan-switch analysis, one S/NS subject was matched to one SOT subject (1:1). For either analysis (triptan-naïve or triptanswitch ), the propensity score for each subject was defined as the probability of receiving S/NS contingent on the following pre-index criteria: age; gender; geographic region; CCI score; number of unique diagnoses; diagnosis of depression/anxiety; use of migraine prophylactic medications; number of antiemetic medications; migraineseverity score; monthly number of tablets of NSAIDs and opioids; number of migraine-related hospitalizations, emergency department visits, physician/outpatient and other outpatient visits in the month immediately preceding the index date; and number of migraine-related hospitalizations, ED visits, physician/outpatient and other outpatient visits in the remaining 5-month pre-index period. Matching was done using the technique of nearest-available matching on the estimated propensity score and was performed up to three decimal places (0.001).
Using the matched samples, regression models were used to assess differences between S/NS and SOT groups. A negative binomial regression model (for count data) was used to assess differences in migraine medication use (number of tablets) and the number of migraine-related visits and all-cause visits. Logistic regression modeling (for whether event occurred) was used to compare the presence of migraine-related and all-cause visits. Finally, a generalized linear model with a log-link function and gamma distribution for the error term was used to assess differences in healthcare costs (migraine-related and pharmacy) between the S/NS and SOT groups. While no specific testing was done to evaluate the fit of the model, the gamma distribution with log-link was selected as it often provides the best fit for cost data.
All statistical analyses were conducted using SAS version 9.1.3 statistical software (SAS Institute Inc., Cary, NC, USA). Statistical significance was evaluated at the 0.05 significance level (two-sided) with no adjustments for multiplicity performed. Additional information on the propensity score matching and regression modeling may be found in the Technical Appendix provided as electronic supplemental material on the journal's web site (http://rd. springer.com/journal/40258).
Results
For the triptan-naïve analysis, a total of 33,614 subjects had an index prescription for S/NS or SOT during the enrollment period. Exclusion criteria applied to this starting population are shown in Table 1 , along with the number of patients excluded because of each criterion. The majority of subjects were excluded for either no continuous eligibility in the pre-or post-index period (66.8 %) or no migraine diagnosis in the pre-or post-index period (58.6 %). The final sample size for the triptan-naïve analysis consisted of 4,398 subjects (S/NS group: 376 and SOT group: 4,022). For the triptan-switch analysis, a total of 6,792 subjects had an existing SOT prescription fill and switched to another SOT or S/NS during the enrollment period. Applying the exclusion criteria to this starting population resulted in a total of 847 subjects (S/NS group: 187 and SOT group: 660) ( Table 1 ). Similar to the triptannaïve analysis, the primary reasons for exclusion were no continuous eligibility in the pre-or post-index period (58.3 %) and no migraine diagnosis in the pre-or postindex period (42.4 %).
Triptan-Naïve Analysis
There were significant baseline differences between the S/NS group and the SOT group in the prematched sample (Table 2 ). Significant differences were noted for the proportion of female patients, region, anti-emetic prescription fill, migraine severity score, and migraine-related healthcare resource use (emergency department visits in the 1 month preceding the index prescription and physician/ outpatient visits in the 2-6 months preceding the index prescription). After propensity-score matching there were 1,384 subjects (S/NS group: 346 and SOT group: 1,038) with no statistically significant differences in baseline characteristics.
The results of the regression models for the matched samples based on the triptan-naïve analysis are presented in Tables 4 and 5 . There were few statistically significant differences between the S/NS and SOT groups with respect to migraine medications used (triptans, NSAIDs, opioids, ergots, and other migraine medications), measured in terms of the average number of tablets in the 6-month post-index period (Table 4 ). An increase in the average number of migraine medication tablets used was observed when comparing pre-index use with post-index use. The SOT group tended to increase their use of migraine medication post-index (S/NS vs. SOT: 17.6 vs. 28.1; p = 0.061), compared with pre-index use, with significant differences between the S/NS and SOT groups noted for opioids (8.6 vs. 18.3; p = 0.045) and ergots (-0.1 vs. 0.0; 0.031).
Migraine-related and all-cause healthcare resource use (excluding pharmacy use) were also similar between the S/NS and SOT groups (Table 4) .
Average migraine-related total costs trended lower for the S/NS group (US$744) compared with the SOT group (US$820) for a difference of US$76, but the difference was not statistically significant (p = 0.067) ( Table 5 ). On average, pharmacy costs were greater in the S/NS group compared with the SOT group (US$492 vs. US$440; p = 0.148), but were offset by reduced medical costs (US$252 vs. US$380; p = 0.001). Significant differences between the S/NS and SOT groups were observed for medical costs across the individual settings of care, including hospitalization (US$10 vs. US$80; p \ 0.001), emergency department visits (US$33 vs. US$111; p = 0.014), and physician/outpatient visits (US$110 vs. US$138; p \ 0.001). The difference in other outpatient visits favored the SOT group (US$100 vs. US$50; p \ 0.001). In terms of all-cause total costs, average costs were significantly lower in the S/NS group compared with the SOT group (US$4,391 vs. US$4,870; p = 0.040) for a difference of US$479. Similar to the results of the migraine-related costs, pharmacy costs were higher in the S/NS group compared with the SOT group (US$1,368 vs. US$1,271; p = 0.416), but were offset by lower medical costs (US$3,023 vs. US$3,599; p = 0.014).
Triptan-Switch Analysis
There were significant baseline differences between the S/NS group and the SOT group in the prematched sample (Table 3 ). Significant differences were noted for age, region, and migraine severity score. After propensity-score matching, there were 260 subjects (S/NS group: 130 and SOT group: 130) with no statistically significant differences in baseline characteristics.
The results of the regression models for the matched samples based on the triptan-switch analysis are presented in Tables 4 and 5 . There were no statistically significant differences between the S/NS and SOT groups with respect to migraine medications used (average number of tablets) in the 6-month post-index period (Table 4) . Similar to the triptan-naïve analysis, the SOT group tended to increase their use of migraine medication post-index compared with the pre-index period (S/NS vs. SOT: 2.5 vs. 17.6; p = 0.378). Of interest is the change in the average number of opioids used, with the SOT group increasing their post-index use of opioids and the S/NS decreasing their post-index use (-8.2 vs. 17.7; p = 0.120). There were no other statistically significant differences between the S/NS and SOT groups for migraine-related or all-cause healthcare resource use with the exception of all-cause hospitalizations (0.03 vs. 0.05; p = 0.034) ( Table 4) . No significant differences were observed for average migraine-related total costs (US$1,159 vs. US$1,117; p = 0.929) and all-cause totals (US$5,128 vs. US$4,788; p = 0.381) when comparing the S/NS group with the SOT group (Table 5) .
Discussion
The goal of effectively managing migraine headaches is to treat attacks rapidly and consistently without recurrence, restore the patient's ability to function, minimize the use of rescue medications, optimize self-care and reduce subsequent use of resources, be cost effective for overall management, have minimal or no adverse events, and to reduce the risk of progression of more frequent headache [24, 54] . Evidence-based treatment guidelines recommend triptans and NSAIDs as the most effective acute treatment for attacks of migraine in adults [24, 29, 30] . However, when used as monotherapy, triptans and NSAIDs (not to mention the other migraine medications) do not provide broad coverage of the multiple pathogenic processes associated with migraine headaches. In this regard, randomized clinical trials of a fixed-dose single-tablet combination of sumatriptan succinate (equivalent to sumatriptan 85 mg) and naproxen sodium 500 mg demonstrated a synergistic effect of the combination, where the efficacy of the S/NS was greater than either of its individual components [31] [32] [33] [34] [35] [36] [37] [38] .
Such a synergistic effect in a fixed-dose combination for the acute treatment of migraine would be expected to improve ''real-world'' outcomes realized in terms of reduced pill burden and treatment regimen complexity, improve patient adherence, reduce healthcare resource use and associated costs, as well as improve patient outcomes. The present study is one of the first studies to examine S/NS and assess healthcare resource use and associated direct medical costs (medical and pharmacy) in a cohort of triptan-naïve and triptan-experienced subjects. The results of these 6-month triptan-naïve and triptan-switch analyses suggest that patients initiated on S/NS are likely to have similar healthcare resource use patterns as those either Dx diagnosis, N number, Rx prescription, S/NS fixed-dose combination sumatriptan succinate 85 mg and naproxen sodium 500 mg, SOT singleentity oral triptan a Criteria are not mutually exclusive newly initiated on an SOT or switching SOTs, as measured by migraine medication use, migraine-related healthcare resource use, and all-cause healthcare resource use. Total costs from the triptan-naïve analysis indicated that the S/NS group compared with the SOT group had lower migraine-related (US$744 vs. US$820; p = 0.067) and all-cause healthcare costs (US$4,391 vs. US$4,870; p = 0.040) when compared with the SOT group. While pharmacy costs were higher in the S/NS group, likely a reflection of the increased drug acquisition cost associated with S/NS, the increase was offset by cost savings in healthcare resource use. Total costs from the triptan-switch analysis were similar between the two groups (S/NS vs. SOT; migraine-related healthcare costs: US$1,159 vs. US$1,117; p = 0.929; all-cause healthcare costs: US$5,128 vs. US$4,788; p = 0.381).
Closer assessment of the differences in migraine medication use (e.g., measured in terms of the mean number of tablets prescribed) is warranted. First, caution is required when interpreting the mean number of tablets as there may be differences in the manner in which the specific medications are administered (e.g., once daily vs. twice daily) as well as the number of tablets dispensed per prescription (e.g., six tablets per prescription vs. nine tablets per prescription). Next, there was an increase in the use of triptans and NSAIDs associated with the S/NS group in both the triptan-naïve and triptan-switch analyses. While not statistically significant, this observation is inconsistent with the notion that a fixed-dose combination would reduce pill burden. However, when examining the pre-and post-index change in migraine medication use there was a non-significant trend in favor of S/NS with a significant change noted for opioids (change in mean number of tablets preindex vs. post-index, S/NS vs. SOT; triptan-naïve analysis: 8.6 vs. 18.3; p = 0.045; triptan-switch analysis: -8.2 vs. 17.7; p = 0.120). While there is a place for opioids for the acute treatment of migraine (e.g., for individuals with contraindications, problems with tolerability, or lack of response to simple analgesics or migraine-specific medications), they are generally not recommended; [55] and, if used, should be considered a second-or third-tier treatment for migraine following simple analgesics and migrainespecific medications [24, 56] . This recommendation is based on studies that have demonstrated that opioids can be associated with an increased risk of medication overuse headache [57] , a dose-dependent increase in the risk of new-onset chronic migraine [58, 59] , and that they may be misused or abused leading to opioid abuse or dependence [56, 57, 60] . A similar finding for the trend in increased use of NSAIDs, albeit among the S/NS group compared with the SOT group (non-significant increase), should also be noted. As naproxen sodium is already a component of S/NS, adding NSAIDs in addition to S/NS may expose individuals to an increased risk of NSAID-related adverse events, including acute liver failure and kidney toxicity/ damage. One of the hypotheses to this study was that the fixeddose combination of S/NS would lead to improved ''realworld'' outcomes, realized in terms of reductions in migraine-related healthcare resource use and associated costs, based on the efficacy observed in the randomized clinical trials, where the efficacy of S/NS was observed to be greater than that of the individual components. However, the present study indicated that those subjects initiated on S/NS are likely to have similar healthcare resource use patterns as those either newly initiated on an SOT or switching SOTs. One explanation for this finding is that the effectiveness of S/NS as an acute migraine treatment extends beyond healthcare resource use and associated costs; thus, the benefits of S/NS cannot solely be measured Rather, the improved ''real-world'' outcomes associated with S/NS may be represented more accurately by improvements in patient outcomes such as functioning, productivity, and health-related quality of life and satisfaction, attributes not captured in administrative claims data. For example, in the pivotal randomized clinical trials, S/NS demonstrated statistically significant clinical benefits compared with either of the individual components that was accompanied by improved patient health outcomes (e.g., functional status, productivity, and satisfaction) [31, 40] . Similarly, a 12-month, open-label, phase III study in 565 subjects with at least 6 months' history of migraine headaches treating nearly 25,000 migraine attacks reported a high level of satisfaction based on the revised Patient Perception of Migraine Questionnaire and improved health-related quality of life based on the Migraine-Specific Quality of Life Questionnaire [41] . Finally, results from two randomized, double-blind, placebo-controlled, multi-attack, crossover studies demonstrated the rapid and consistent restoration of patients' functioning, the consistent reduction in productivity loss, and high satisfaction ratings from patients treating multiple migraine attacks with S/NS using an early-intervention approach [61] . As with any study, these results must be interpreted within the context of the study's limitations. Extrapolation of study results to the general migraine population is a potential limitation. However, given that migraine prevalence rates peak between the ages of 35 and 45 years, the most productive years of life and the age most likely to reflect the population with some level of healthcare benefits/insurance [62, 63] , the condition is likely to be fairly represented in an administrative claims database. As with all retrospective analyses of administrative claims data, inclusive of the present study, potential errors in coding, incomplete claims, and missing information are limitations that should be considered. Furthermore, the data obtained from administrative claims databases have not been validated with medical record reviews. In terms of the current study design, there were differences in the baseline ED emergency department, HCRU healthcare resource use, N number, NSAID non-steroidal anti-inflammatory drug, S/NS fixed-dose combination sumatriptan succinate 85 mg and naproxen sodium 500 mg, SD standard deviation, SOT single-entity oral triptan characteristics of the study sample. While propensity score matching addressed these differences, the matching was based on a series of proxy measures to account for migraine severity, a clinical parameter not found in administrative claims data. To the extent that these proxy measures are fairly representative of actual migraine severity, the comparison of outcomes may be considered valid between the matched cohorts. However, residual confounding may exist if the underlying severity is not adequately captured by these proxy measures. Another limitation of the study is that subjects were followed for a relatively short period of 6 months owing to availability of data at the time of analyses. Another study design consideration is the ability to compare the fixed-dose combination of S/NS with its prescribed individual components (e.g., prescription for sumatriptan 85 mg and naproxen sodium 500 mg, respectively). The challenge to conducting this analysis is the lack of a marketed sumatriptan 85-mg tablet (approved dosages are 25 mg, 50 mg, and 100 mg) and the over-the-counter availability of naproxen sodium, which is typically not found in administrative claims. Finally, the triptan-switch analysis was based on small sample sizes, which limits the statistical power to detect differences between the groups and was dependent on the definition of 'switch,' which was broadly defined as at least one prescription for a different SOT or S/NS.
Conclusions
The results of the triptan-naïve and triptan-switch analyses suggest that subjects initiated on S/NS are likely to have similar healthcare resource use patterns as those either newly initiated on a SOT or switching SOTs. For subjects newly initiating S/NS or a SOT (i.e., the triptan-naïve analysis), the S/NS group was associated with lower migraine-related and all-cause healthcare costs when compared with the SOT group. In the triptan-switch analysis, migraine-related and all-cause healthcare costs were similar across the two groups. While the current study focuses on direct medical costs, future studies should extend beyond such a perspective to explore functional status, productivity, health-related quality of life, and satisfaction, attributes not captured in administrative claims data, but nonetheless important treatment goals.
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